Manufacturing of Cytotoxic and Non-Cytotoxic Drugs in a Multiproduct Facility

When different drug products are produced in shared facilities, the potential for crosscontamination is always a concern that needs to be addressed. Drug products provide a benefit to the intended patient; however, as a cross-contaminant they can pose a risk. This is especially true when manufacturing oncology drugs, as many of them are highlypotent substances with cytotoxic or genotoxic effects, while others are not.

More White Papers / Tech Papers by Baxter BioPharma Solutions

Assurance of the vacuum integrity of freeze - dryers used for the manufacture of sterile pharmaceutical products is essential for GMP operations; however, there is currently no generally accepted scientific rationale for establishing acceptance crite…

Formulation, process, and analytical development for antibody - drug conjugates, or ADCs, is complex. While the development of an aqueous solution formulation may be preferred over a lyophilized product, it is useful to initially pursue a dual path a…

A common approach to process development for lyophilized products is to thermally characterize the solution formulation to determine the critical product temperature that should not be exceeded during primary drying. This is conducted using different…

Formulation and process development for injectable products are typically conducted at laboratory-scale. Laboratory-scale equipment is useful and necessary during development when there is little technical information available and especially when th…

The ultimate goal of formulation development is a stable product. In the case of a protein product, that can be defined as delivering the correct dose, in the native secondary and tertiary structure, without unintended chemical modifications, and fre…

Baxter’s BioPharma Solutions facility in Bloomington, Indiana, was recognized for the fifth time as Best Contract Manufacturing Organization at the annual Vaccine Industry Excellence (ViE) Awards, held during the 2017 World Vaccine Congress in…

Experience Makes the Difference
Optimizing lyophilization cycle times and improving stability for complex injectables is a critical component of parenteral product development. With this understanding, BioPharma Solutions established the Lyophiliz…

Baxter has been honored to be recognized globally with various awards and distinctions by the industry, as well as by sustainability, community support and environmental organizations. Download the attached for a sampling, with a full list available…

Yes, I would like to learn more about Baxter BioPharma Solutions, Please contact me by Phone or Email.

Loading, Please Wait..

Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies. You can obtain detailed information about the use of cookies on our website by clicking on "More information”.